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Prostate-specific antigen (PSA) kinetics predicts survival in castration-resistant prostate cancer 
(CRPC); however, the influence of prior treatment on this relationship is unclear. Patients with CRPC 
were stratified according to time to PSA nadir and time to CRPC progression to investigate their 
prognostic significance on prostate cancer-specific survival (PCSS) and whether PSA kinetics may serve 
as prognosticators regardless of prior local treatment. This multicenter retrospective study included 
295 patients diagnosed with CRPC between September 2009 and November 2017. PSA kinetics during 
androgen-deprivation therapy (ADT) including %PSA decline, PSA nadir level, time to PSA nadir, and 
time to CRPC progression was investigated. Subgroup analysis was performed according to the prior 
history of local curative treatment. Patients who did not receive prior local treatment with ≥6 months 
to PSA nadir and <12 months to CRPC, showed lower PCSS rates than those with <6 months to PSA 
nadir (23.3% vs. 45.3%; p = 0.031) and ≥12 months to CRPC (20.0% vs. 47.8%; p = 0.001). In patients 
who had received local treatment, PSA kinetic parameters did not influence PCSS. Our results indicate 
that time to PSA nadir and time to CRPC progression are prognosticators of PCSS in patients with CRPC 
who did not previously receive curative local treatment.
Prostate cancer (PCa) shows a protracted natural history with heterogeneous outcomes, depending on the 
treatment modality1. In order to deliver optimal treatment and maximize survival outcomes, it is imperative to 
develop and validate clinical predictors that can distinguish high-risk patients who may be candidates for active 
treatment from low-risk patients who can be offered less aggressive therapy.
Prostate-specific antigen (PSA) is the most widely used biomarker of disease burden and treatment response 
during PCa therapy2,3. Observations of the PSA level and of PSA kinetics have been utilized as predictive indi-
cators of disease progression. Controversy exists in relation to the prognostic impact of PSA kinetics on PCa 
survival. Since the 1990s, several reports have suggested that analysis of PSA kinetics prior to PCa diagnosis 
could predict tumor grade, stage, and time to disease recurrence following radical prostatectomy (RP)4–6. A more 
diverse approach to the prognostic value of PSA kinetics has been reported since 2000. Studies have analyzed the 
prognosis of PCa in relation to PSA kinetics prior to treatment, and have suggested that a rapid increase in the 
PSA level before treatment predicted a relatively high risk of mortality from PCa7,8. Moreover, observations of 
PSA levels after local treatments such as RP or radiation therapy (RT) have reported that PSA doubling time and 
time to PSA nadir were significantly associated with prostate cancer-specific survival (PCSS)9–11. In patients with 
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metastatic PCa treated with androgen deprivation therapy (ADT), a decrease in PSA velocity during ADT was 
reported to associate with survival12–16.
To the best of our knowledge, no study has analyzed the prognostic impact of PSA kinetics during ADT 
on PCSS in patients stratified according to their prior history of local tumor treatment, and who later received 
various novel approved agents targeting castration-resistant PCa (CRPC), including abiraterone, enzalutamide, 
233radium, and cabazitaxel. To address this issue, the present study investigated the utility of PSA kinetics during 
ADT, and of prior local tumor therapy with curative intent, for the prediction of PCSS in patients diagnosed with 
CRPC. Despite the approval of various CRPC treatments, and new clinical trials promoting the use of these agents 
in combination, there is insufficient evidence on which treatment and when to apply such treatment would confer 
an optimal oncological outcome. Therefore, this specific patient population was selected in order to distinguish 
high-risk CRPC patients who should be offered active treatment from low-risk patients who may be managed 
with less aggressive therapy.
Results
Baseline clinicopathological characteristics. The clinicopathological features of the patients included 
in the analysis, stratified by their time to PSA nadir and time to CRPC progression, are described in Table 1. The 
median age and PSA upon PCa diagnosis were 66.5 years and 55.8 ng/mL, respectively. Among the total of 295 
patients, 149 (50.5%) patients underwent prior local treatment: RP in 121 (81.2%) patients and RT in 28 (18.8%) 
patients. 220 (74.6%) patients had a primary metastatic disease at initial diagnosis, and 75 (25.4%) patients had 
localized or locally advanced disease. There were no statistically significant differences in the total duration of 
salvage ADT between patients who received RP and RT (p = 0.468).
Age, body mass index, PSA, Gleason score, N stage, and metastatic site (except bone) did not differ in the 
groups stratified by time to PSA nadir or time to CRPC. However, patients with <12 months to CRPC had a lower 
prevalence of stage ≥T3 disease (p = 0.009) and a higher prevalence of metastatic disease at initial PCa diagnosis 
(p = 0.009). At the time of CRPC diagnosis, serum ALP level showed significant differences according to time 
to PSA nadir (p = 0.044) and time to CRPC (p = 0.001). Patients who had a PSA nadir at ≥6 months exhibited 
higher CCI than those who had a PSA nadir at <6 months (p = 0.013).
Supplementary Table 1 describes the treatments administered following CRPC diagnosis. There were no 
differences in the proportions of docetaxel, androgen receptor axis-targeted agents, cabazitaxel, and 233radium 
administrations or enrollment in clinical trials between patient subgroups. However, patients with ≥12 months 
to CRPC received more docetaxel cycles than those with <12 months to CRPC.
Survival outcomes. Table 2 shows the outcomes of CRPC patients, stratified according to prior local cura-
tive therapy and PSA kinetics during ADT. Figure 1 illustrates PCSS curves, stratified by time to the PSA nadir 
dichotomized at six months. In patients who had received prior local treatment, there were no difference in the 
2-year PCSS outcomes (42.9% vs. 50.4%; p = 0.421) (Fig. 1B). However, among patients who did not receive prior 
curative treatment, men who had PSA nadir at ≥6 months showed lower 2-year PCSS rates than did those with a 
PSA nadir at <6 months (23.3% vs. 45.3%; p = 0.031) (Fig. 1C).
Figure 2 illustrates PCSS curves, stratified by time to CRPC progression dichotomized at 12 months. Lower 
PCSS rates were observed in patients with CRPC progression at <12 months for both prior local treatment 
(37.6% vs. 54.1%; p = 0.017), and no prior local treatment (20.0% vs. 47.8%; p = 0.001) groups.
Predictors of PCSS. Univariate and multivariate models of predictors of prostate cancer-specific mortality 
(PCSM) are shown in Table 3. In the overall group, multivariate analysis identified stage ≥T3, Gleason score ≥8, 
Eastern Cooperative Oncology Group performance status ≥2, serum albumin and ALP levels, time to CRPC <12 
months, and no prior local therapy as significant predictors of PCSM. Table 4 shows that in patients who did not 
undergo curative local therapy, stage ≥T3, Eastern Cooperative Oncology Group performance status ≥2, serum 
albumin and ALP levels, time to PSA nadir ≥6 months, and time to CRPC <12 months were significant predic-
tors of PCSM. In patients who had received previous curative local therapy, there were no significant relationships 
between PSA kinetics and PCSM (Table 5).
Discussion
A comprehensive set of clinicopathological factors at ADT initiation and PSA kinetics observed during ADT, 
were analyzed to investigate predictors of PCSS in patients who later developed CRPC. In the current era of mul-
timodal therapies targeted at CRPC, we focused on this specific population in order to deliver an optimal treat-
ment strategy for individual patients. Since disease progression may be affected by the treatment of the primary 
tumor, patients were stratified according to their previous history of curative local treatment. In patients who 
had not received curative local treatment, those with PSA nadir at ≥6 months and time to CRPC of <12 months 
showed lower rates of 2-year PCSS, compared to patients with PSA nadir at <6 months and time to CRPC of ≥12 
months. However, in patients who had received curative local treatment, time to PSA nadir did not influence 
PCSS. Patients who are at high risk of disease progression should be identified at an early stage using PSA kinetics 
and history of curative local treatment and receive active treatment, while low-risk patients can be managed with 
less aggressive therapy.
Multimodal strategies exist for PCa treatment, ranging from active surveillance to aggressive combined ther-
apies, with heterogeneous survival outcomes. PSA kinetics is considered to represent a prognostic marker of PCa 
progression. Many previous reports have investigated PSA kinetics in patients receiving systemic therapies for 
BCR and metastatic PCa. However, to our knowledge, our study is the first to consider whether a prior history 
of curative local treatment influences the prognostic value of PSA kinetics, after adjusting for a comprehensive 
set of clinicopathological data. A noteworthy finding was the PCSS benefit observed with local treatment in 
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patients with CRPC. Our results add to existing literature that local treatments targeted at the primary tumor in 
patients with castration-naïve PCa may confer a survival benefit in the disease course of CRPC progression. Still, 
a cautious interpretation would be warranted in that 25.4% of our cohort did not exhibit de novo metastasis at the 
diagnosis of PCa.
Some of our findings contrasted with those of previous studies. Several previous reports suggested that PSA 
kinetic parameters such as PSA doubling time and time to PSA nadir were significant predictors of survival in 
patients who had received curative treatment. However, these studies were limited by the differences in patient 
Overall (n = 295)
Time to PSA nadir Time to CRPC progression
<6 months 
(n = 218)
≥6 months 
(n = 77) p
≥12 months 
(n = 237)
<12 months 
(n = 58) p
At initial PCa diagnosis
Age (years) 66.5 (61.0–71.8) 66.0 (61.0–71.0) 68.0 (63.0–73.0) 0.546 66.5 (61.0–71.0) 66.5 (60.8–72.3) 0.864
BMI (kg/m2) 24.1 (21.9–25.7) 24.1 (22.1–25.7) 24.1 (21.7–25.7) 0.823 24.2 (22.0–25.8) 23.9 (21.8–25.8) 0.763
PSA (ng/mL) 55.8 (18.2–335.3) 50.0 (15.0–175.6) 92.9 (26.1–414.4) 0.445 53.6 (18.2–212.0) 87.6 (18.0–470.6) 0.138
Gleason score 0.678 0.140
≤7 60 (20.3%) 40 (24.3%) 20 (26.0%) 50 (21.1%) 10 (17.2%)
≥8 235 (79.7%) 178 (75.7%) 57 (74.0%) 187 (78.9%) 48 (82.8%)
T stage 0.194 0.009
≤T2 109 (36.9%) 71 (32.5%) 38 (49.4%) 78 (32.9%) 31 (53.4%)
≥T3 186 (63.1%) 147 (67.4%) 39 (50.6%) 159 (67.1%) 27 (46.6%)
N stage 0.090 0.766
N0 125 (42.4%) 100 (45.9%) 26 (33.8%) 102 (43.0%) 23 (39.7%)
N1 170 (57.6%) 118 (54.1%) 51 (66.2%) 135 (57.0%) 35 (60.3%)
M stage 0.127 0.009
M0 75 (25.4%) 51 (24.4%) 24 (31.2%) 67 (28.3%) 8 (13.8%)
M1 220 (74.6%) 167 (75.6%) 53 (68.8%) 170 (71.7%) 50 (86.2%)
Metastatic site
Bone 167 (56.6%) 128 (76.6%) 39 (73.6%) 0.620 122 (71.8%) 45 (90.0%) 0.015
Visceral 15 (5.1%) 12 (7.2%) 3 (5.7%) 0.327 10 (5.9%) 5 (10.0%) 0.441
Lymph node 147 (49.8%) 110 (65.9%) 37 (69.8%) 0.403 117 (68.8%) 30 (51.7%) 0.769
Extent of metastases 0.708 0.915
<5 sites 120 (54.5%) 94 (56.3%) 26 (49.1%) 91 (53.5%) 29 (58.0%)
≥5 sites 100 (45.5%) 73 (43.7%) 27 (50.9%) 79 (46.5%) 21 (42.0%)
Prior local treatment 149 (50.5%) 104 (47.7%) 45 (58.4%) 0.071 124 (52.3%) 25 (43.1%) 0.197
Radiation therapy 28 (18.8%) 19 (18.3%) 9 (20.0%) 0.456 22 (17.7%) 6 (24.0%) 0.096
Prostatectomy 121 (81.2%) 85 (81.7%) 36 (80.0%) 0.486 102 (82.3%) 19 (76.0%) 0.246
At ADT
Initial PSA (ng/mL) 55.9 (18.2–255.2) 23.8 (4.4–125.9) 62.2 (17.2–409.2) 0.149 23.6 (3.7–123.6) 68.7 (12.3–327.9) 0.063
PSA at nadir (ng/mL) 0.47 (0.10–3.06) 0.54 (0.10–3.14) 0.38 (0.08–3.28) 0.474 0.28 (0.07–2.04) 2.55 (0.70–10.3) 0.468
Time to nadir (months) 4.0 (2.0–7.0) 3.0 (2.0–4.0) 10.0 (7.0–13.0) <0.001 5.0 (2.0–8.0) 2.0 (1.0–3.0) <0.001
%PSA decline (≥90%) 218 (73.9%) 154 (70.6%) 68 (88.3%) 0.004 182 (76.8%) 36 (62.1%) 0.058
Time to CRPC (months) 28.0 (13.0–52.0) 11.0 (8.0–17.0) 43.0 (24.5–60.5) <0.001 36.0 (20.0–60.0) 9.0 (6.5–10.0) <0.001
At CRPC progression
PSA (ng/mL) 69.2 (15.0–182.0) 71.8 (15.3–228.3) 58.3 (12.5–154.0) 0.113 70.5 (14.9–189.0) 67.6 (17.3–175.7) 0.805
Hemoglobin (g/dL) 12.0 (10.7–13.0) 12.2 (10.4–13.1) 11.8 (10.8–12.8) 0.343 12.0 (10.6–13.1) 12.1 (10.9–13.0) 0.371
Albumin (g/dL) 4.0 (3.7–4.4) 4.0 (3.7–4.4) 4.1 (3.8–4.4) 0.220 4.0 (3.7–4.4) 4.1 (3.7–4.5) 0.530
ALP (IU/L) 109.0 (70.0–209.0) 119.0 (77.0–241.0) 86.0 (62.5–180.8) 0.044 97.5 (68.0–193.0) 156.0 (97.5–406.5) 0.001
CCI 0.013 0.240
≤1 140 (47.5%) 113 (51.8%) 27 (35.1%) 108 (45.6%) 32 (55.2%)
≥2 155 (52.5%) 105 (48.2%) 50 (64.9%) 129 (54.4%) 26 (44.8%)
ECOG PS 0.886 0.061
≤1 159 (53.9%) 127 (58.3%) 32 (41.6%) 124 (52.3%) 35 (60.3%)
≥2 136 (46.1%) 91 (41.7%) 45 (58.4%) 113 (47.7%) 23 (39.7%)
Table 1. Clinicopathological characteristics of patients stratified according to prostate-specific antigen kinetics 
during androgen-deprivation therapy. Data are median (interquartile range) and number (%). ADT, androgen 
deprivation therapy; ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson Comorbidity Index; 
CRPC, castration-resistant prostate cancer; ECOG PS, Eastern Cooperative Oncology Group performance 
status; PCa, prostate cancer; PSA, prostate-specific antigen.
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baseline characteristics and the absence of a clear definition of BCR, which is an important criterion for ADT ini-
tiation following local therapy. Zhou et al. proposed PSA doubling time and Gleason score as predictors of PCSM 
following RP or RT9. Of note, most of the patients were in the early stages of the disease with favorable Gleason 
score and T stage compared to our cohort. Furthermore, the PSA level used to confirm ‘PSA-defined recurrence’ 
was not clearly specified. The median PSA level upon ADT initiation was 9.4 ng/mL in RP patients and 9.8 ng/mL 
in RT patients. D’Amico et al. also identified an association between time to PSA nadir and PCSM in patients with 
BCR after local therapy11. In this study, more than 50% of the patients exhibited Gleason score ≤6. In contrast, 
our patients exhibited higher Gleason score and TNM stage since the retrospective data collection was limited to 
patients who later developed CRPC. The PSA working group criteria for PSA failure were used in the D’Amico et 
al. study, rather than the 2018 EAU-ESTRO-ESUR-SIOG guidelines17,18. Moreover, patients with >20 ng/mL PSA 
at the initiation of ADT were also included. Despite the controversy regarding the optimal PSA value to define 
BCR, it would be arduous to apply these findings to contemporary patients19,20. This implies that the PSA cutoff 
used to define BCR sensitively influences prognostic data interpretation. In the present study, all patients were 
followed and managed according to contemporary treatment guidelines, suggesting that our results are general-
izable to the contemporary PCa population.
The relationship between time to PSA nadir and survival outcome is controversial. Some studies reported 
that shorter time to PSA nadir associated with improved PCSS11,15,21. In contrast, others reported that shorter 
time to PSA nadir was associated with reduced overall survival14,16,22,23. A rapid decline of PSA during ADT 
is generally considered to correlate with more hormone sensitivity in the PCa cells, and less development of 
androgen-independent PCa cells, accompanied by a longer remission period and improved survival21. One of the 
reasons for the contrary results is presumed to be the ablation of the androgen receptor, which acts as a tumor 
suppressor13. However, the relationship between this molecular tumor feature and overall survival has not been 
fully elucidated. Moreover, the endpoint of this cited study was sequential increases in PSA levels, rather than sur-
vival. Thus, direct comparisons cannot be made between these studies due to differences in patient characteristics, 
BCR definitions, and primary endpoints.
Our study was strengthened by the incorporation of a wide range of potential prognosticators, the availa-
bility of detailed clinicopathologic data, and information on treatment outcomes, which were available from all 
patients. Most importantly, the independent survival prognosticators identified here are those readily available in 
everyday clinical practice; this increases their general applicability. At the same time, we acknowledge several lim-
itations of the study. First, this was a retrospective study and sampling intervals used to estimate PSA kinetics dur-
ing ADT were not therefore defined prospectively or standardized. Second, the treatments administered were not 
uniformly selected. Although there were no statistically significant differences between the treatments employed 
for CRPC, the possibility of bias due to subgroup differences cannot be overlooked. For instance, there was a 
difference in the number of docetaxel cycles administered to patients stratified according to the time to CRPC. 
This suggests that there may have been greater chemo-tolerance in patients who received more chemotherapeutic 
cycles, which might have affected our results. Third, as our study population included patients who were relatively 
older and had multiple comorbidities, PCSS was chosen as the end point of our study instead of overall survival. 
Lastly, the treatment paradigm for castration sensitive PCa is rapidly evolving with accumulating evidence that 
upfront chemotherapy and androgen receptor axis-targeted agents may improve PCSS. Therefore, the results of 
our study may not apply to patients receiving these multimodal treatments. Despite these limitations, our study 
Overall 
(n = 295)
Time to PSA nadir Time to CRPC progression
<6 months 
(n = 218)
≥6 months 
(n = 77) p
≥12 months 
(n = 237)
<12 months 
(n = 58) p
PCSS, 2-year (%)
Overall group 46.8% 47.0% 28.4% 0.012 51.4% 27.4% <0.001
Prior curative local 
treatment 51.6% 50.4% 42.9% 0.421 54.1% 37.6% 0.017
No prior curative local 
treatment 41.2% 45.3% 23.3% 0.031 47.8% 20.0% 0.001
CRPC to death period (months)
Overall group 16.0 (9.0–27.3) 17.0 (10.0–28.0) 12.5 (5.0–19.5) 0.118 17.5 (9.8–28.0) 15.0 (8.0–22.5) 0.098
Prior curative local 
treatment 18.0 (11.0–29.0) 18.0 (11.0–29.0) 19.0 (12.0–31.5) 0.550 18.0 (11.0–29.0) 19.0 (13.0–29.0) 0.851
No prior curative local 
treatment 15.0 (7.0–25.0) 15.0 (8.0–26.3) 9.0 (5.0–16.5) 0.036 15.0 (8.0–27.3) 12.0 (6.0–18.0) 0.048
Total follow-up period (months)
Overall group 19.0 (10.3–29.0) 19.0 (11.0–29.0) 16.0 (9.0–31.5) 0.738 20.0 (11.0–32.0) 15.0 (7.5–23.0) 0.067
Prior curative local 
treatment 19.0 (11.3–31.0) 19.0 (12.0–31.0) 13.0 (11.0–28.0) 0.750 19.5 (11.0–32.8) 18.0 (13.0–27.8) 0.260
No prior curative local 
treatment 17.0 (8.0–28.0) 19.0 (9.3–29.0) 13.5 (7.5–18.8) 0.015 21.0 (10.0–30.0) 12.0 (6.5–20.0) 0.003
Table 2. Survival outcomes of patients stratified according to prior curative local treatment and prostate-
specific antigen kinetics. Data are number (%) and median (IQR). CRPC, castration-resistant prostate cancer; 
PCSS, prostate cancer-specific survival; PSA, prostate-specific antigen.
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provides meaningful data indicating that PSA kinetics cannot be utilized as an independent prognostic marker in 
all PCa patients and should be interpreted in the context of previous curative local therapy.
In conclusion, time to PSA nadir and time to CRPC onset during ADT are prognosticators of PCSS in patients 
with CRPC who did not previously receive local curative treatment. In contrast, PSA kinetics may not be useful 
as a prognosticator of PCSS in patients who have received curative local therapy. Further larger scale analyses 
are warranted to define the influence of local treatment on ADT pharmacokinetics and on the future response to 
CRPC treatment.
Methods
Patient selection and data collection. Clinicopathological data were collected from two Korean insti-
tutions: Severance Hospital and Gangnam Severance Hospital (Yonsei University Health System). A total of 295 
consecutive patients who were diagnosed with CRPC progression between September 2009 and November 2017 
were included in this multicenter retrospective study.
Patients with de novo metastasis were given ADT as initial treatment, and no patient was offered intermittent 
ADT. RP or RTx with or without ADT were performed for patients with localized or locally advanced disease, 
and those with a limited metastatic burden. Surgery was performed by the retropubic or robotic approach, with 
the extent of pelvic lymph node dissection based upon the risk category of the patient. RT consisted of intensity 
modulated external beam RT with the median RT dose of 7,000 cGy (IQR 7,000 to 7,000) (Fig. 3).
The criteria for confirming biochemical recurrence (BCR) after receiving RP included a PSA level of ≥0.2 ng/
mL24,25. Patients exhibiting BCR following RP without radiologic recurrence received salvage RT with short-term 
ADT. Long-term ADT was initiated following further radiographic disease progression. BCR following RT 
was defined as a rise of ≥2.0 ng/mL above the nadir26. ADT was initiated following BCR. The CRPC diagnostic 
Figure 1. Kaplan-Meier curves showing cumulative cancer-specific survival, stratified by time to PSA nadir 
(dichotomized at 6 months) in the (A) overall group (n = 295), (B) patients who had received previous curative 
local therapy (n = 149), and (C) patients who had not received previous curative local therapy (n = 146).
Figure 2. Kaplan-Meier curves showing cumulative cancer-specific survival, stratified by time to castration-
resistant prostate cancer (dichotomized at 12 months) in the (A) overall group (n = 295), (B) patients who had 
received previous curative local therapy (n = 149), and (C) patients who had not received previous curative local 
therapy (n = 146).
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Figure 3. Flow diagram of the patient cohort involved in this study. ADT, androgen deprivation therapy; 
CRPC, castration-resistance prostate cancer; PCa, prostate cancer; RP, radical prostatectomy; RT, radiation 
therapy
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
At PCa diagnosis
Age 1.023 (0.996–1.050) 0.098
BMI 0.986 (0.922–1.056) 0.694
T stage (≥T3 vs. ≤T2) 1.563 (1.058–2.309) 0.025 1.941 (1.381–2.730) <0.001
N stage (1 vs. 0) 1.629 (0.736–3.645) 0.226
M stage (1 vs. 0) 1.117 (0.739–1.690) 0.599
Metastatic sites (≥5 vs. ≤4) 1.118 (0.791–1.582) 0.527
Gleason score (≥8 vs. ≤7) 1.848 (1.259–2.813) 0.002 2.019 (1.433–2.844) <0.001
Prior local therapy (yes vs. no) 0.517 (0.383–0.699) <0.001 0.534 (0.368–0.775) 0.001
PSA kinetics following ADT
PSA level at ADT initiation 1.000 (1.000–1.001) 0.635
%PSA decline (≥90%) 0.874 (0.556–1.374) 0.560
PSA nadir level (≥10 ng/ml) 1.328 (0.692–2.549) 0.394
Time to PSA nadir (≥6 months) 1.338 (0.853–2.100) 0.204
Time to CRPC (<12 months) 2.062 (1.458–2.813) <0.001 2.106 (1.157–4.101) 0.015
At CRPC progression
PSA 1.000 (1.000–1.001) <0.001 1.000 (1.000–1.001) 0.425
Hemoglobin 1.001 (1.000–1.003) 0.115
Albumin 0.468 (0.318–0.688) <0.001 0.674 (0.477–0.952) 0.025
ALP 1.001 (1.001–1.002) <0.001 1.001 (1.001–1.001) <0.001
Testosterone 1.278 (0.634–2.412) 0.345
CCI (≥2 vs. ≤1) 1.602 (0.914–2.809) 0.100
ECOG PS (≥2 vs. ≤1) 2.803 (2.232–3.617) 0.001 2.968 (1.404–6.277) 0.004
Table 3. Multivariable analyses of prostate cancer-specific mortality in all patients with castration-resistant 
prostate cancer. ADT, androgen-deprivation therapy; ALP, alkaline phosphatase; BMI, body mass index; CCI, 
Charlson Comorbidity Index; CI, confidence interval; CRPC, castration-resistant prostate cancer; ECOG 
PS, Eastern Cooperative Oncology Group performance status; HR, hazards ratio; PCa, prostate cancer; PSA, 
prostate-specific antigen.
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Univariate Multivariate
HR (95% CI) p HR (95% CI) p
At PCa diagnosis
Age 1.020 (0.979–1.063) 0.334
BMI 1.092 (0.981–1.216) 0.108
T stage (≥T3 vs. ≤T2) 1.336 (0.728–2.455) 0.350
N stage (1 vs. 0) 0.559 (0.162–1.890) 0.367
M stage (1 vs. 0) 1.370 (0.866–2.165) 0.178
Metastatic sites (≥5 vs. ≤4) 1.035 (0.585–1.831) 0.906
Gleason score (≥8 vs. ≤7) 2.253 (1.156–4.390) 0.017 2.949 (1.412–6.160) 0.004
PSA kinetics following ADT
PSA level at ADT initiation 0.999 (0.998–1.001) 0.216
%PSA decline (≥90%) 0.657 (0.338–1.275) 0.657
PSA nadir level (≥10 ng/ml) 1.441 (0.582–3.656) 0.429
Time to PSA nadir (≥6 months) 1.969 (0.924–4.192) 0.079
Time to CRPC (<12 months) 1.832 (1.100–3.050) 0.020 1.225 (0.687–2.185) 0.492
At CRPC progression
PSA 1.001 (1.000–1.001) <0.001 1.003 (1.001–1.005) 0.002
Hemoglobin 1.002 (1.000–1.003) 0.035
Albumin 0.641 (0.326–1.261) 0.198
ALP 1.002 (1.001–1.003) 0.002 2.090 (0.940–4.647) 0.071
Testosterone 1.435 (0.567–1.944) 0.474
CCI (≥2 vs. ≤1) 0.829 (0.445–1.584) 0.839
ECOG PS (≥2 vs. ≤1) 2.446 (1.051–5.692) 0.038 3.966 (1.270–12.38) 0.018
Table 5. Multivariable analyses of prostate cancer-specific mortality in patients with a previous history of curative local 
treatment. ADT, androgen-deprivation therapy; ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson 
Comorbidity Index; CI, confidence interval; CRPC, castration-resistant prostate cancer; ECOG PS, Eastern Cooperative 
Oncology Group performance status; HR, hazards ratio; PCa, prostate cancer; PSA, prostate-specific antigen.
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
At PCa diagnosis
Age 1.025 (0.995–1.055) 0.099
BMI 0.900 (0.834–0.971) 0.007
T stage (≥T3 vs. ≤T2) 1.783 (1.159–2.741) 0.008 1.911 (1.165–3.135) 0.010
N stage (1 vs. 0) 1.296 (0.808–2.047) 0.288
M stage (1 vs. 0) 0.574 (0.318–1.035) 0.065
Metastatic sites (≥5 vs. ≤4) 1.009 (0.976–1.042) 0.607
Gleason score (≥8 vs. ≤7) 1.925 (1.272–2.913) 0.002 1.489 (0.880–2.522) 0.138
PSA kinetics following ADT
PSA level at ADT initiation 1.515 (1.103–2.066) 0.021 2.002 (0.993–4.033) 0.068
%PSA decline (≥90%) 0.891 (0.555–1.430) 0.632
PSA nadir level (≥10 ng/ml) 1.923 (1.050–3.523) 0.034
Time to PSA nadir (≥6 months) 2.424 (1.771–3.311) 0.002 2.501 (1.309–4.778) 0.006
Time to CRPC (<12 months) 2.122 (1.326–3.394) 0.002 2.768 (1.467–5.223) 0.002
At CRPC progression
PSA 1.001 (1.000–1.001) 0.002 1.001 (1.000–1.001) 0.070
Hemoglobin 0.782 (0.704–0.868) 0.001 0.906 (0.771–1.063) 0.225
Albumin 0.335 (0.230–0.488) <0.001 0.333 (0.199–0.558) 0.001
ALP 1.002 (1.001–1.003) <0.001 1.002 (1.001–1.003) 0.002
Testosterone 1.338 (0.749–2.716) 0.147
CCI (≥2 vs. ≤1) 1.266 (0.846–1.895) 0.251
ECOG PS (≥2 vs. ≤1) 2.854 (1.329–4.813) <0.001 2.193 (1.023–4.700) 0.044
Table 4. Multivariable analyses of prostate cancer-specific mortality in patients without a previous history of curative 
local treatment. ADT, androgen-deprivation therapy; ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson 
Comorbidity Index; CI, confidence interval; CRPC, castration-resistant prostate cancer; ECOG PS, Eastern Cooperative 
Oncology Group performance status; HR, hazards ratio; PCa, prostate cancer; PSA, prostate-specific antigen.
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criteria followed the recommendation of the 2018 EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer18. 
These criteria were: castrate serum testosterone <50 ng/dL or 1.7 nmol/L plus either; (a) biochemical progression: 
three consecutive rises in PSA one week apart resulting in two 50% increases over the nadir, and a PSA >2.0 ng/
mL, or (b) radiological progression: the appearance of new lesions: either two or more new bone lesions on bone 
scan or a soft tissue lesion using Response Evaluation Criteria in Solid Tumours27. This retrospective study was 
approved by Institutional Review Board of Yonsei University (2017-0186-001), which waived the requirement for 
informed consent. All study procedures complied with the principles of the 1946 Declaration of Helsinki, and its 
2008 update.
Clinicopathological data included age, body mass index, PSA, Gleason score, T stage, N stage, M stage, and 
metastatic sites at the time of initial PCa diagnosis. PSA kinetics analyzed included the PSA nadir level, time 
to PSA nadir, %PSA decline, and time to CRPC, based on the initial PSA at the time of ADT initiation. Serum 
PSA, hemoglobin, albumin, and alkaline phosphatase (ALP) levels, the Charlson comorbidity index, and Eastern 
Cooperative Oncology Group performance status score were collected at CRPC diagnosis.
Patients with CRPC were stratified according to time to PSA nadir dichotomized at six months, and time to 
CRPC progression dichotomized at 12 months to investigate the prognostic significance of PSA kinetics on PCSS. 
Subgroup analyses were performed according to the prior history of local curative treatment.
Statistical analyses. The study groups were compared using the two-sided Mann–Whitney U test (for the 
analysis of continuous variables) and the chi-square test (for the analysis of two or more variables). Variables 
considered as potential predictors for multivariate modeling were selected by univariate analyses using the 
Cox-proportional hazards regression model. The optimal cut-off value for each PSA kinetic parameter was deter-
mined by reference to the maximum of the Youden index in each receiver operating characteristic curve28.
To compare the survival outcomes of each patient group, Kaplan-Meier survival analysis was performed 
according to time to PSA nadir and time to CRPC, dichotomized at 6 and 12 months, respectively. All statistical 
analyses were performed using IBM SPSS software (version 21.0; IBM Corporation, Armonk, NY, USA) and R 
statistical package (version 3.2.0; Institute for statistics and mathematics, Vienna, Austria). Differences with a 
p-value of <0.05 were considered statistically significant.
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